论文部分内容阅读
由于与大多数慢性粒细胞白血病(CML)患者相匹配的同种异基因供体缺乏,以及常规疗法对CML的不可治愈性,自体移植日益增多。迄今已报告200例,晚期移植者一般能重建慢性期,但持续时间短;慢性期移植效果较好,移植后大多数能延长慢性期,改善存活状况,约60％病人部分或完全ph染色体阴性,有些持续4年以上。为进一步提高CML自体移植效能,应致力于寻求更有效的移植前抗白血病疗法,以及开创更切实可靠的去除移植物中CML细胞的新方法。
Due to the lack of allogeneic donor matching to most chronic myelogenous leukemia (CML) patients and the incurability of conventional therapy for CML, autologous transplantation is increasing. 200 cases have been reported so far. Late stage transplants can generally reconstruct the chronic phase but have a short duration. The transplantation in the chronic phase is effective. Most of the patients can prolong the chronic phase and improve their survival after transplantation. About 60% of patients have partial or complete ph-chromosomal negative results. Some lasted for more than 4 years. To further improve the efficacy of CML autotransplantation, efforts should be made to seek more effective anti-leukemia therapy before transplantation and to create new and more reliable methods for removing CML cells from grafts.